Illumina (ILMN) financials
TrendArc score 50 of 100 · Health 8.6 · Momentum 2.8 · Moat 4.6 · scored Nov 17, 2026 · How the score works
Illumina revenue and earnings by year
Illumina's revenue was $4.34 billion in the fiscal year to December 28, 2025, down 0.7% from the year before. Net income was $850 million, 19.6% of revenue. Since the fiscal year to January 1, 2017, revenue has grown 6.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
What stands out
- Revenue fell in each of the last 3 fiscal years, from $4.6 billion in the fiscal year to January 2023 to $4.3 billion in the fiscal year to December 2025.
Each sentence is written by a fixed rule from the figures on this page.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Jan 2023 | Jan 2022 | Jan 2021 | Dec 2019 | Dec 2018 | Dec 2017 | Jan 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.34 | 4.37 | 4.50 | 4.58 | 4.53 | 3.24 | 3.54 | 3.33 | 2.75 | 2.40 |
| Revenue growth | -0.7% | -2.9% | -1.7% | 1.3% | 39.7% | -8.6% | 6.3% | 21.1% | 14.8% | — |
| Gross profit | 2.87 | 2.86 | 2.74 | 2.97 | 3.15 | 2.20 | 2.47 | 2.30 | 1.83 | 1.67 |
| Gross margin | 66.1% | 65.4% | 60.9% | 64.8% | 69.7% | 68.0% | 69.6% | 69.0% | 66.4% | 69.5% |
| Operating income | 0.81 | -0.83 | -1.07 | -4.18 | -0.12 | 0.58 | 0.98 | 0.88 | 0.61 | 0.59 |
| Operating margin | 18.6% | -19.1% | -23.7% | -91.2% | -2.7% | 17.9% | 27.8% | 26.5% | 22.0% | 24.5% |
| Net income | 0.85 | -1.22 | -1.16 | -4.40 | 0.76 | 0.66 | 1.00 | 0.83 | 0.73 | 0.46 |
| Net margin | 19.6% | -28.0% | -25.8% | -96.1% | 16.8% | 20.3% | 28.3% | 24.8% | 26.4% | 19.3% |
| Diluted EPS | $5.45 | -$7.66 | -$7.14 | -$27.22 | $4.88 | $4.33 | $6.57 | $5.41 | $4.80 | $3.01 |
| Free cash flow | 0.93 | 0.71 | 0.28 | 0.11 | 0.34 | 0.89 | 0.84 | 0.85 | 0.56 | 0.51 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app, under Fundamentals on the full chart: open ILMN in TrendArc Charts.
Illumina revenue and margins against its peers
| Company | Fiscal year to | Revenue | Revenue growth | Operating margin | Net margin |
|---|---|---|---|---|---|
| IlluminaILMN | Dec 2025 | $4.34B | -0.7% | 18.6% | 19.6% |
| Mettler ToledoMTD | Dec 2025 | $4.03B | 4.0% | 27.3% | 21.6% |
| IQVIAIQV | Dec 2025 | $16.3B | 5.9% | 13.4% | 8.3% |
| WatersWAT | Dec 2025 | $3.17B | 7.0% | 25.4% | 20.3% |
| Agilent TechnologiesA | Oct 2025 | $6.95B | 6.7% | 21.3% | 18.8% |
| Charles River LaboratoriesCRL | Dec 2025 | $4.02B | -0.9% | 0.6% | -3.6% |
| Bio-TechneTECH | Jun 2026 | $1.22B | -0.4% | 20.7% | 15.0% |
| Peer median | 4.9% | 21.0% | 16.9% |
See also: ILMN valuation and P/E history · ILMN returns
No forecast, no recommendation. This page describes Illumina from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.